sign in sign up
<<
Home , Femoxetine

The British Journal of Psychiatry (2015) 206, 93–100. doi: 10.1192/bjp.bp.114.148551

Data supplement

Table DS1 Study characteristics Risk of bias assessment Duration Diagnostic criteria, Number of Mean duration Adequate Blinding of participants, Incomplete Free from of minimum severity participants n Total leaving Predominant of trauma Age, year sequence Allocation personnel and outcome data selective Free from Study, location Design, intervention, dose range and mean treatment and duration of illness (% female) the study n trauma type (%) symptoms Mean (range) Outcome measures generation concealment outcome assessors addressed reporting other bias

Baker (1995)60 Multicentre, randomised, double-blind, parallel, 12 weeks DSM-III-RCAPS >45MADRS 146 (19) 35 Combat (60) 12.8 years 44 (23–73) CAPSIES Unclear Unclear Unclear High High Unclear USA placebo-controlled, flexible dose brofaromine up to 150 mg 522 46 months Brady (2000)38 Multicentre, randomised, double-blind, parallel, placebo- 12 weeks DSM-III-RCAPS >50>6 187 (73) 50 Sexual assault (61) 12 years 40 (18+) CAPSDTSIESCGI-SCGI-IHRSD Unclear Unclear Unclear Unclear Low High USA controlled, flexible dose 50–200 mg (133.3 mg) months Brady (2005)61 Randomised, double-blind, parallel, placebo-controlled, fixed dose 12 weeks DSM-IVConcurrent 94 (46) Physical assault (50) 36.7 (18–65) CAPSHRSD Low Unclear Unclear High Low Unclear USA sertraline 50–150 mg alcoholism use severity Braun (1990)62 Randomised, double-blind, cross-over, placebo-controlled, 2 week 5 weeks DSM-III 13 (0) 6 Combat (40) 4.3 years 37.7 DSM-based PTSD Unclear Unclear Unclear Unclear Unclear Unclear Israel titrated placebo washout flexible dose alprazolam scaleIESHRSDHRSAVAS 1.5–6 mg (4.65 mg) Butterfield (2001)39 Randomised, double-blind, parallel, placebo-controlled, flexible 10 weeks DSM-IV 15 (93) 4 Rape (53) 43.2 (18–70) DTSIESSPRINTTOP-8 Unclear Unclear Unclear Low Low High USA dose 5–20 mg (14.1 mg) Carey (2012)31 Single centre, randomised, double-blind, parallel, placebo- 8 weeks DSM-IVCAPS >50>3 34 10 Domestic violence 40.5 CAPSDTSMADRSCGISDS Unclear Low Unclear Unclear Low High South Africa controlled, flexible dose olanzapine 5–15 mg (9.2 mg) months (60% female of n = 28) and criminal violence (range 18+ of n = 28) Connor (1999)40 Randomised, double-blind, parallel, placebo-controlled, flexible 12 weeks DSM-III-R 54 (91) 17 Rape (26) 6 years 32 (18–55) DGRSSIPDTSSDSVS Low Low Unclear Unclear Low Unclear USA dose 10–60 mg (30 mg) Connor (2005)17 Responders to open label treatment randomised to double-blind, 12 weeks DSM-IVCGI-S >4 18 (0) 5 18–65 SPRINTSIPCGI- Unclear Unclear Unclear Unclear Low High USA placebo-controlled discontinuation phase, flexible dose tiagabine discontinuation SDTSHRSDCD-RISCPSQISDI 4–16 mg (10.8 mg) phase DavidsonA Multicentre, randomised, double-blind, placebo-controlled, 12 weeks DSM-IVCAPS >60DTS 538 (65) 218 Non-sexual abuse (26) 32 (18+) CAPSCGI-SDTSGAF Unclear Unclear Unclear High Low High USA parallel flexible dose 37.5-300mg (164.4mg) v. >40>6 months sertraline 25–200 mg (110.2 mg) Davidson (1990)41 Randomised, double-blind, parallel, placebo-controlled, flexible 8 weeks DSM-III 46 (0) 13 Combat (100) CGI-ISI-PTSDCGI- Unclear Unclear Unclear Low Low Unclear USA dose 50–300 mg (169 mg) SHRSDHRSAIESNIEPI Davidson (2001)42 Multicentre, randomised, double-blind, parallel, placebo- 28 weeks DSM-III-RCAPS-2 450 96 (30) 48 Physical or sexual 13.05 years 43 (21–69) CGI-SCGI-IIESCAPS Unclear Unclear Unclear Unclear Low High USA controlled, flexible dose sertraline 20–200 mg (137 mg), relapse 46 months assault (52) prevention following open label study Davidson (2001)43 Multicentre, randomised, double-blind, parallel, placebo- 12 weeks DSM-III-RCAPS-2 208 (22) 77 Physical/sexual 12.2 years 37.1 (18–69) CGI-ICGI-SIESCAPS Low Unclear Unclear Unclear Low High USA controlled, flexible dose sertraline 50–200 mg (146.3 mg) 45046 months assault (62) Davidson (2003)44 Randomised, double-blind, parallel, placebo-controlled, fixed 8 weeks DSM-IVSIP 29 (0) 6 Mixed 46.5 SPRINTCGI-I Unclear Unclear Unclear Unclear Low High USA dose 15–45 mg (38.8 mg) Davidson (2004)45 Remission data pooled from two double-blind placebo-controlled 12 weeks DSM-III-RCAPS 450 384 (75) 127 Physical/sexual assault 12.1 years 38 (18–69) CGI-SCGI-IDTSIESCAPS-2 Unclear Unclear Unclear Unclear Unclear Unclear USA 12-week flexible dose sertraline comparison trials 46 months Davidson (2005)82 Six months open label treatment followed by 6 months 6 months MINI criteria 62 (50) 32 Combat (32) 44.1 (18–70) SPRINTCGI-SDTS Unclear Unclear Unclear Unclear High Unclear USA randomised, double-blind, placebo-controlled, flexible dose (discontinuation fluoxetine 10–60 mg (48.6 mg) phase) Davidson (2006)18 Multicentre, randomised, double blind, parallel, placebo- 24 weeks DSM-IVCAPS 460 329 (54) 105 Assault (57) 41.35 (18+) CAPS-SX17CGI-SGAFHRSD- Low Unclear Low Low Low High International controlled, flexible dose venlafaxine 37.5–300 mg (181.7 mg) 46 months 17CD-RISC SVSQ-LES-Q-SFSDS Davidson (2007)19 Multicentre, randomised, double blind, parallel, placebo- 12 weeks DSM-IVCAPS 232 (56) 91 Physical/sexual 13.1 years 42.6 (16–64) CAPSDTSTOP-8CGI-CCDR- Unclear Unclear Unclear High High Unclear USA controlled, flexible dose tiagabine 4–16 mg (11.2 mg) 450DTS 450 assault (53) SSDSMGSQMADRS Davis (2001)46 Randomised, double-blind, parallel, placebo-controlled, flexible 12 weeks DSM-IV 42 (2) 19 Combat (98) 29.9 years 53.8 (32–75) CAPSHRSAHRSDPTSD Unclear Low Low Low Low High USA dose 200–600 mg (435 mg) checklistCADSSGAFSCGI Davis (2008)20 Randomised, double-blind, parallel, placebo-controlled, flexible 8 weeks DSM-IVCAPS 445 85 (2) 17 Combat (95) 24.4 years 55.2 (19–70) CAPSTOP-8MADRSCGI- Low Low Low Unclear Low Low USA dose divalproex 500–3000 mg (2309 mg) SCGI-IHRSA Eli LillyB Randomised, double-blind, placebo-controlled, parallel arm, 12 weeks 411 (0) 259 CGI-STOP-8 Unclear Unclear Unclear High High High fixed dose fluoxetine 20 mg v. 40 mg Friedman (2007)21 Multicentre, randomised, double-blind, parallel, placebo- 12 weeks DSM-III-RCAPS 4546 169 (21) 40 Combat (71) 18 years 45.5 (18+) CAPSIESCGI-ICGI- Low Unclear Low Unclear Low Unclear USA controlled, flexible dose sertraline 50–200 mg (135 mg) months SDTSHRSAHRSDPSQIDESMISS Huaihai22 Preventative, randomised, double-blind, placebo-controlled, 1 month DSM-IVHealthy population 53 (41) 0 Natural disaster (100) 36.4 (18+) PCLPTSD self-rating scale Unclear Unclear Unclear Low High Unclear China flexible dose 10–20 mg Hertzberg (1999)63 Randomised, double-blind, parallel, placebo-controlled, flexible 12 weeks DSM-IVSIP 15 (36) 6 Combat (71) 43.4 (29–53) SIPDGRP Unclear Unclear Unclear Low High High USA dose lamotrigine 25–500 mg (380 mg) Hertzberg (2000)47 Randomised, double-blind, parallel, placebo-controlled, flexible 12 weeks DSM-III-R 12 (0) 1 Combat (100) 46 (44–48) DGRPDTSSDSSIP Unclear Unclear Unclear Unclear High Unclear USA dose fluoxetine 10–60 mg (48 mg) Katz (1994)48 Multicentre, randomised, double-blind, parallel, placebo- 14 weeks DSM-III-RCAPS 436 68 (24) 23 Physical assault (38) 2.8 years 39 (22–62) CAPSCGI Unclear Unclear Unclear High High High USA controlled, flexible dose brofaromine 50–150 mg Kosten (1991)49 Multicentre, randomised, double-blind, parallel, placebo- 8 weeks DSM-III 60 (0) 28 Combat (100) 39 IESHRSAHRSDRSDCAS Unclear Unclear Unclear Low Low Unclear USA controlled, flexible dose 50–300 mg (225 mg) v. phenelzine 15–75 mg (68 mg) Marshall (2001)50 Multicentre, randomised, double-blind, parallel, placebo- 12 weeks DSM-IV 563 (57) 208 Physical/sexual 15.7 years 41.8 (18+) CAPS-2CGI-IDTSTOP- Unclear Unclear Unclear High Low High USA controlled, fixed dose paroxetine 25 mg v. 50 mg assault (48–54) 8SDSMADRS Marshall (2004)64 Randomised, double-blind, parallel, placebo-controlled, flexible 10 weeks DSM-IV43 months 63 (0) 33 Physical assault 39.8 (18–65) CAPSCGIIPPDESHRSAHRSD Unclear Unclear Unclear High Low High USA dose paroxetine 10–60 mg. Maintenance phase not included or abuse (48) Martenyi (2002)52 Acute phase, multicentre, randomised, double-blind, parallel, 12 weeks DSM-IVCAPS-DX 301 (19) 139 Combat (47) 37.9 (18–65) TOP-8CAPSCGI-SCGI- Low Low Unclear Unclear Low High International placebo-controlled, flexible dose fluoxetine 20–80 mg (57.8 mg) 450CGI-S 44 IMADRSHRSASCL-90-RDES Martenyi (2002)51 Continuation phase, multicentre, randomised, double-blind, 24 weeks DSM-IVCAPS-DX 131 (19) 33 Non-combat (53) 5.15 years 38.3 (18–65) TOP-8CAPSCGI-SCGI- Low Low Unclear Low Low High International parallel, placebo-controlled, flexible dose fluoxetine 20–80 mg 450CGI-S 44 IMADRSHRSASCL-90-RDES (57.8 mg) Martenyi (2007)23 Multicentre, randomised, double-blind, parallel, placebo- 12 weeks DSM-IVCAPS >50, CGI-I >4 411 (71) 64 Sexual assault (78) 40.7 (18–75) TOP-8CAPSDTSCGI- Unclear Unclear Unclear Unclear Low Low USA controlled, fixed dose fluoxetine (20 mg, 40 mg) SMADRSHRSADES Matthew (2011)24 Multicentre, randomised, double blind, parallel, placebo- 8 weeks DSM-IVCAPS >50CGI-S 47 (59) 16 Physical/sexual 11.4 years (18-65) CAPSDTSCGI-IMADRSCGI- Low Low Low Unclear High High USA controlled, fixed dose GR205171 5 mg >4>3 months assault (72) SSDS McRae (2004)65 Randomised, double-blind, parallel arm, flexible dose nefazodone 12 weeks DSM-IVCAPS-S >50 after 37 (0) 40.3 (18–65) CAPS-SCGI- Unclear Unclear Unclear Unclear Low High USA 100–600 mg (463 mg) v. sertraline 50–200 mg (153 mg) placebo run-in>3 months IDTSMADRSHRSATOP-8PSQISDS Padala (2006)25 Randomised, double blind, parallel, placebo-controlled, flexible 12 weeks 20 (100) 8 41.3 (19–65) CAPSTOP-8HRSDHRSA Unclear Unclear Unclear High High Unclear USA dose risperidone 4–6 mg (2.62 mg) Panahi (2011)26 Randomised, double blind, parallel, placebo-controlled, flexible 10 weeks DSM-IV-TRCGI-S >4>6 70 (0) 8 Combat (100) 24.1 years 45.6 IES-RCGI-S Low Unclear Low Low Low Unclear Iran dose sertraline 50–200 mg (140 mg) months Petrakis (2012)32 Multicentre, randomised, double-blind, parallel, placebo-controlled, DSM-IV529/7 abstinent ? = 88 (9) (n =44in 7 (monotherapy) Combat (92) 47.1 CAPSHRSD Unclear Unclear Unclear Low Low Unclear USA flexible dose paroxetine 10–40 mg (39.7 mg) v. monotherapy groups) 25–200 mg (187.2 mg) (naltrexone groups not considered) Pfizer588C Multicentre, randomised placebo-controlled, double-blind, parallel, 74 days DSM-III-RCAPS-2 >50 193 (75) 50 Physical/sexual assault 10.5 years 37 CAPS-2CGI-IIESDTSCGI-S Unclear Unclear Unclear High High High flexible dose trial sertraline (156 mg) Pfizer589D Randomised, double-blind, placebo-controlled, parallel flexible 72 days DSM-III-R 169 (20) 40 Combat (71) 18 years 45 CGI-SCGI-IIESDTSCAPS-2 Unclear Unclear Unclear High High High dose trial sertraline (156 mg) Reist (1989)66 Multicentre, randomised, double blind, cross-over, placebo- 8 weeks DSM-III-R 27 (0) 9 Combat (100) 38.4 (28–64) IESHRSDHRSABDI Unclear Unclear Unclear High Low Unclear USA controlled, flexible dose desipramine 50–200 mg (165 mg) Saygin (2002)67 Randomised, double-blind, parallel arm, flexible dose nefazodone 24 weeks DSM-IV 60 (0) 6 Earthquake survivors 41.5 TOP-8CGI-ICGI-SCGI-SE Unclear Unclear Unclear High Low Unclear Turkey 200–400 mg (332.4 mg) v. sertraline 50–100 mg (68.3 mg) Shalev (2011)27 Randomised, double-blind, parallel, placebo-controlled, fixed dose 20 weeks DSM-IVCAPS 440, no 46 (44) 7 RTA (83) 144.1 days 38.6 (18–70) CAPSPSS-SR Low Unclear Low Unclear Low Unclear Israel 10–20 mg minimum duration SKB627E Randomised, double-blind, parallel, placebo-controlled, flexible 84 days DSM-IV 322 (53) 18–75 CAPS-2CGI-I Unclear Unclear Unclear High High High dose paroxetine 20–50 mg SKB650F Randomised, double-blind, placebo-controlled, flexible dose 252 days DSM-IVCAPS 450 176 (66) 46 43 (18–82) CAPS-2DTSMADRSSDS Unclear Unclear Unclear High High High paroxetine up to 50 mg Spivak (2006)28 Randomised, double blind, parallel, head-to-head comparator, 8 weeks DSM-IVCAPS 460 40 (47) 12 RTA (100) 40.1 CAPSTOP-8HRSDHRSA Low Unclear Low High Low High Israel fixed dose 8 mg v. 150 mg 41 month Tucker (2001)53 Multicentre, randomised, double blind, parallel arm, placebo- 12 weeks DSM-IV 323 (66) 152 14.9 years 40.8 (18–78) CAPS-2CGI-IDTSTOP- Unclear Unclear Unclear High Low High USA controlled, flexible dose paroxetine 20–50 mg (27.6 mg) 8SDSMADRS Tucker (2003)68 Randomised, double blind, parallel, placebo-controlled, flexible 10 weeks DSM-IVCAPS >50 59 (72) 14 Physical abuse/assault (31) 38.5 (18–64) CAPSIESBDI Unclear Unclear Unclear High Low High USA dose 20–50 mg (36.2 mg) v. sertraline 50–200 mg (134.1 mg) Tucker (2007)29 Randomised, double blind, parallel, placebo-controlled, flexible 8 weeks DSM-IVCAPS >50No 40 (80) 6 Childhood sexual abuse 41.5 (18–65) CAPSHRSAHRSDTOP-8CGI- Low Unclear Unclear Low Low Unclear USA dose topiramate25–400 mg (150 mg) minimum duration (34) SCGI-IDTSBISSDSCD-RISC Van der Kolk (1994)69 Multicentre, randomised, double-blind, parallel arm, placebo- 5 weeks DSM-III-R 64 (34) 17 Combat (44) 40.4 (22–55) CAPSBDHIHRSDDESDESI Unclear Unclear Unclear High Low High USA controlled, flexible dose fluoxetine 20–60 mg (40 mg) Van der Kolk (2004)70 Multicentre, randomised, double-blind, parallel arm, placebo- 5 weeks DSM-IV>12 months 59 (86) 7 Interpersonal victimisation 13.1 years 34.9 (18–65) CAPSBDI Unclear Unclear Unclear Low Low Low USA controlled, flexible dose fluoxetine 10–60 mg v. EMDR (72) Yeh (2010)30 Randomised, double blind, parallel, placebo-controlled 12 weeks DSM-IV 35 (68) 21 Violence (100) 40.1 (18–62) CAPSBDICGI Low Unclear Unclear Low Low Unclear Bra-zil topiramate 50–200 mg (102.9 mg) Zohar (2002)54 Multicentre, randomised, double-blind, parallel arm, placebo- 10 weeks DSM-III-RCAPS-2 450 51 (37/42) 20 Combat (32/42) 40 (18+) CAPS-2CGI-ICGI-SMADRSLOCF Unclear Unclear Unclear High Low High Israel controlled, flexible dose sertraline 50–200 mg (120 mg) CGI-S 4446 months (1 post-baseline assessment)

BDHI, Buss–Durkee Hostility Inventory; BDI, Beck Depression Inventory; CADSS, Clinician Administered Dissociative States Scale; CAPS, Clinician Administered PTSD Scale; CAPS-2, CAPS part 2; CAPS-DX, CAPS Diagnosis; CAPS-SX17, CAPS Symptom 17-item; CAS, Covi Anxiety Scale; CDRS-R, Children’s Depression Rating Scale Revised; CD-RISC, Connor–Davidson Resilience Scale; SVS, Sheehan Stress Vulnerability Scale; CGI, Clinical Global Impression (C, change; I, improvement; S, severity); DES, Dissociative Experiences Scale; DESI, Disorders of Extreme Stress Inventory; DGRP, Duke Global Rating for PTSD; DTS, Davidson Trauma Scale; EMDR, eye movement desensitisation and reprocessing; EPI, Eysenck Personality Inventory; GAF, Global Assessment of Functioning; HRSA, Hamilton Rating Scale for Anxiety; HRSD, Hamilton Rating Scale for Depression; IES, Impact of Events Scale; IPP, Inventory of Personal Problems; LOCF, last observation carried forward; MADRS, Montgomery–A˚ sberg Depression Rating Scale; MISS, Mississippi Scale for Combat-Related PTSD; NI, Newcastle Index; PCL, Psychopathy Checklist; PSQI, Pittsburgh Sleep Quality Index; PSS, PTSD Symptoms Scale; PSS-SR, PSS self-rated; QLES Q-SF, Quality of Life Enjoyment and Life Satisfaction Short Form; RSD, Raskin Scale for Depression; RTA, road traffic accident; SCL-90-R, Hopkins 90-item Symptom Checklist Revised; SDS, Sheehan Disability Scale; SI-PTSD, DSM-based PTSD scale; SIP, Structured Interview for PTSD; SPRINT, Short PTSD Rating Interview scale; TOP-8, Treatment Outcome PTSD Scale; VAS, Visual Analog Scale; VS, Vulnerability to the Effects of Stress Scale. Appendix DS1 Electronic search strategy

1. Stress Disorders, Traumatic/ or Combat Disorders/ or Stress Disorders, 40. or/26-39 Post-Traumatic, Acute/ or Stress Disorders, Post-Traumatic/ or Stress, 41. animals/ not (animals/ and human$.mp.) Psychological/ 42. animal$/ not (animal$/ and human$/) 2. Stress, Psychological/ or Critical Incident Stress/ or Stress Disorders, Post-Traumatic/ 43. meta-analysis/ 3. Posttraumatic Stress Disorder/ or Emotional Trauma/ or Traumatic 44. meta-analysis.pt. Neurosis/ 45. systematic review/ 4. Posttraumatic Stress Disorder/ or Psychotrauma/ 46. or/41–45 5. (post?traumatic$ or post-traumatic$ or stress disorder$ or acute stress 47. 25 not 46 or PTSD or ASD or DESNOS).tw. 48. pharmacother*.tw 6. (combat neuros$ or combat syndrome or concentration camp 49. pharmacolog*.tw syndrome or extreme stress or flash?back$ or flash-back$ or hypervi- gilan$ or hypervigilen$ or psych$ stress or psych$ trauma$ or 50. *.tw psycho?trauma$ or psycho-trauma$).tw. 51. Psychopharmacology/ 7. (railway spine or (rape adj2 trauma$) or re?experienc$ or re-experienc$ 52. Benzodiazepines/ or torture syndrome or traumatic neuros$ or traumatic stress).tw. 53. antidepressive agents/ 8. (trauma$ and (avoidance or grief or horror or death$ or night?mare$ or night-mare$ or emotion$)).tw. 54. hypnotics/ 9. grief bereav*.tw 55. sedatives/ 10. or/1–9 56. medicat*.tw 11. exp clinical trials/ or cross-over studies/ or random allocation/ or 57. *.tw double-blind method/ or single-blind method/ 58. drug therapy/ 12. random$.pt. 59.ˆAntidepressive Agents¤ 13. exp clinical trial/ or crossover procedure/ or double blind procedure/ 60.ˆMonoamine Oxidase Inhibit ORs¤ or single blind procedure/ or randomization/ 61.ˆSelective Serotonin Reuptake InhibitORs¤ 14. exp clinical trials/ or crossover design/ or random assignment/ 62.ˆTricyclic ¤ 15. exp clinical trials/ or double blind method/ or random allocation/ 63. 16. random$.mp. 64. 17. (cross-over or cross?over or (clinical adj2 trial$) or single-blind$ or 65. Amersergide single?blind$ or doubleblind or double?blind$ or triple-blind or triple?- blind).tw. 66. Amiflamine 18. randomized controlled trial/ 67. 19. matched pair analysis/ 68. Amitriptyline 20. cohort study.tw 69. 21. case-control.tw 70. Befloxatone 22. before-and-after studies.tw 71. 23. epidemiological studies.tw 72. Beta blockers 24. intervention studies.tw 73. Beta*.tw 25. or/11–24 74. Brofaromine 26. mask*.tw 75. 27. blind*.tw 76. 77. Caroxazone 28.ˆlatin square¤.tw 29. placebos/ 78. ChlORpoxiten 30. placebo*.tw 79. Cilosamine 31. random*.tw 80. Cimoxatone 32. research design/ 81. Citalopram 33. comparative study/ 82. 34. evaluation studies/ 83. ClORgyline 35. follow-up studies/ 84. ClORimipramine 36. prospective studies/ 85. Clovoxamine 37. control*.tw 86. Cortisol 38. prospectiv*.tw 87. Deanol 39. volunteer*.tw 88.

2 89. Deprenyl 126. Oxaflozane 90. Desipramine 127. 91. Dibenzipin 128. Pargyline 92. 129. Paroxetine 93. Dothiepin 130. Phenelzine 94. 131. Piribedil 95. 132. Pirlindole 96. Escitalopram 133. Pivagabine 97. 134. Propranol 98. Femoxetine 135. Prosulpride 99. 136. 100. Fluoxetine 137. 101. Fluparoxan 138. Reboxetine 102. Fluvoxamine 139. Rolipram 103. Hydrocortisone 140. Sertraline 104. Idazoxan 141. 105. Imipramine 142. Teniloxine 106. Iprindole 143. Tetrindole 107. Iproniazid 144. Thiazesim 108. isocarboxazid 145. Thozalinone 109. 146. Tianeptine 110. 147. Toloxatone 111. 148. Tomoxetine 112. 149. Tranylcypromine 113. 150. 114. 151. 115. 116. 152. Venlafaxine 117. Minaprine 153. 118. Mirtazapine 154. Viqualine 119. Moclobemide 155. Zimeldine 120. Nefazodone 156. beta blockers 121. Nialamide 157. beta*.tw. 122. 158. cortisol 123. 159. hydrocortisone 124. 160. or/48-159 125. Opipramol 161. 10 and 25 and 40 and 46 and 47 and 159